Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Auxilium Pharmaceuticals Inc. Stories

2013-12-04 16:26:01

CHESTERBROOK, Pa., Dec. 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") announced today that the United States District Court for the District of Delaware ("Court") granted Upsher-Smith Laboratories, Inc.'s ("USL") motion for summary judgment with respect to its attempts to bring a testosterone gel product to market via its 505(b)(2) NDA using Auxilium's Testim® product as its reference listed drug. (Logo:...

2013-11-25 08:26:47

- Six abstracts presented throughout meeting - CHESTERBROOK, Pa., Nov. 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, has announced that new and updated data were presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disease...

2013-11-20 08:28:02

-Multiple Studies of XIAFLEX for the Potential Treatment of Peyronie's Disease to be Presented- CHESTERBROOK, Pa., Nov. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX(®) (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disease, will be presented at the upcoming 19(th) Annual Fall Scientific Meeting of the Sexual...

2013-11-18 08:27:56

- Expects to submit supplemental Biologics License Application to the FDA in the first quarter of 2014 that supports potential labeling expansion for concurrent treatment of multiple palpable cords- CHESTERBROOK, Pa., Nov. 18, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the results of the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's)...

2013-11-12 08:35:32

LYNBROOK, N.Y., Nov. 12, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX(® )(collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) (the EU tradename for CCH) in the EU, today reported its financial results for the third quarter ended September 30, 2013 and provided a corporate update. "We are excited about the potential approval of CCH for Peyronie's...

2013-11-06 08:28:58

- 3Q13 Total Net Revenues Increased by 52% vs. 3Q12 to $108.1 MM - CHESTERBROOK, Pa., Nov. 6, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the quarter ending September 30, 2013. The Company also highlighted select commercial, regulatory and clinical development progress in the third quarter of 2013 and updated guidance for full year 2013. (Logo:...

2013-10-24 08:35:57

CHESTERBROOK, Pa., Oct. 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will release results for the third quarter 2013 on Wednesday, November 6, 2013. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter. The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site...

2013-10-23 12:28:57

- First patient dosed in Phase 2a randomized, double-blind multiple-dose study - LYNBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first patient in its Phase 2a study of XIAFLEX ("collagenase clostridium...

2013-10-23 08:29:58

- Topline Results are Expected in the First Quarter of 2015 - CHESTERBROOK, Pa., Oct. 23, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known as cellulite. As previously reported, Phase 1b open label dose-ranging...

2013-10-11 08:23:42

- STENDRA Broadens Auxilium's Presence in Men's Health Care With a Projected 2013 Launch into the Multi-Billion Dollar Erectile Dysfunction Market - CHESTERBROOK, Pa., Oct. 11, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. (Nasdaq: VVUS) providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada. The...